Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Katzenstein

Showing results (141-150 of 162) with videos related to

Pageof 17
Sort By:
The Journal of Infectious Diseases|March 14, 1998
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 TeamS A Fiscus, M D Hughes, J L Lathey, et al.
AIDS (London, England)|November 24, 1999
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance ProgramD Brambilla, P S Reichelderfer, J W Bremer, et al.
The Journal of Infectious Diseases|March 14, 1998
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 TeamJ L Lathey, M D Hughes, S A Fiscus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2015
Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230Nagalingeswaran Kumarasamy, Evgenia Aga, Heather J Ribaudo, et al.
The Journal of Infectious Diseases|December 26, 2001
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapyJ L Lathey, C Tierney, S Y Chang, et al.
The Journal of Infectious Diseases|September 2, 2005
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapineEsther J Lee, Rami Kantor, Lynn Zijenah, et al.
AIDS (London, England)|March 24, 2012
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settingsJohn A Bartlett, Heather J Ribaudo, Carole L Wallis, et al.
Viruses|January 21, 2023
Insights into HIV-1 Transmission Dynamics Using Routinely Collected Data in the Mid-Atlantic United StatesSeble G Kassaye, Zehava Grossman, Priyanka Vengurlekar, et al.
JAMA|July 11, 1998
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA PanelC C Carpenter, M A Fischl, S M Hammer, et al.
JAMA|July 10, 1996
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USAC C Carpenter, M A Fischl, S M Hammer, et al.
Pageof 17

Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
The Journal of Infectious Diseases|March 14, 1998
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 TeamS A Fiscus, M D Hughes, J L Lathey, et al.
AIDS (London, England)|November 24, 1999
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance ProgramD Brambilla, P S Reichelderfer, J W Bremer, et al.
The Journal of Infectious Diseases|March 14, 1998
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 TeamJ L Lathey, M D Hughes, S A Fiscus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 20, 2015
Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230Nagalingeswaran Kumarasamy, Evgenia Aga, Heather J Ribaudo, et al.
The Journal of Infectious Diseases|December 26, 2001
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapyJ L Lathey, C Tierney, S Y Chang, et al.
The Journal of Infectious Diseases|September 2, 2005
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapineEsther J Lee, Rami Kantor, Lynn Zijenah, et al.
AIDS (London, England)|March 24, 2012
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settingsJohn A Bartlett, Heather J Ribaudo, Carole L Wallis, et al.
Viruses|January 21, 2023
Insights into HIV-1 Transmission Dynamics Using Routinely Collected Data in the Mid-Atlantic United StatesSeble G Kassaye, Zehava Grossman, Priyanka Vengurlekar, et al.
JAMA|July 11, 1998
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA PanelC C Carpenter, M A Fischl, S M Hammer, et al.
JAMA|July 10, 1996
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USAC C Carpenter, M A Fischl, S M Hammer, et al.
Pageof 17